<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952078</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-818-001</org_study_id>
    <nct_id>NCT03952078</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma</brief_title>
  <official_title>A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corvus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral
      interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of
      relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability,
      and anti-tumor activity of CPI-818 as a single drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral
      interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of
      relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability,
      and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose
      escalation and dose expansion cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events following treatment with CPI 818 to establish the safety and tolerability with increasing dose</measure>
    <time_frame>First dose until 30 days after treatment stop</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) of CPI 818 to establish either the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of CPI 818</measure>
    <time_frame>Up to approximately 21 days after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of CPI-818 in blood samples to evaluate the pharmacokinetic profile of CPI 818</measure>
    <time_frame>Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of CPI-818 in blood samples to evaluate the pharmacokinetic profile of CPI 818</measure>
    <time_frame>Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate per Laguno Classification for CTCL and Consensus Statement for Response for CTCL to assess the anti-tumor activity of CPI 818 in subjects with R/R T cell lymphoma</measure>
    <time_frame>From start of treatment through end of study treatment, up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate total percentage of tumor gene expression in post-treatment blood and tumor samples to evaluate pharmacodynamic changes with treatment.</measure>
    <time_frame>Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall percentage of malignant cells in post-treatment blood and tumor samples to evaluate pharmacodynamic changes with treatment.</measure>
    <time_frame>Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CPI-818 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for &gt;2 months or if dose determined to be unsafe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPI-818 Dose Expansion phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.
CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for &gt; 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-818</intervention_name>
    <description>Interleukin-2 inducible T-cell Kinase Inhibitor</description>
    <arm_group_label>CPI-818 Dose Escalation</arm_group_label>
    <arm_group_label>CPI-818 Dose Expansion phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects age â‰¥18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Histologically confirmed evidence of T-cell lymphoma

          -  Measurable disease.

          -  Adequate organ function.

          -  At least 2 standard therapies for advanced or recurrent disease or had a disease for
             which there is no more than one established therapy.

        Exclusion Criteria:

          -  Treatment with systemic immunosuppressive medication.

          -  History of allogeneic hematopoietic stem cell transplantation.

          -  History of primary immunodeficiency, solid organ transplantation.

          -  History of opportunistic infection within 180 days of starting study drug.

          -  Females who are pregnant, lactating, or intend to become pregnant

          -  History of invasive prior malignancy that required systemic therapy within last 3
             years.

          -  Concomitant use of strong inhibitors or inducers of CYP3A.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehrdad Mobasher, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Corvus Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director Clinical Operations</last_name>
    <phone>650-900-4548</phone>
    <email>inquiry@corvuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>650-900-4562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Luciano</last_name>
      <phone>+61 8 6382 5100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggido</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggido</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggido</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggido</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan-Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anahita Mohammady</last_name>
      <phone>6509004562</phone>
      <email>amohammady@corvuspharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

